Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

Ads

You May Also Like

BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan

RESEARCH TRIANGLE PARK, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ...

Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018

MINNEAPOLIS, May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...